Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
16.70
+1.77 (11.86%)
At close: Apr 1, 2026, 4:00 PM EDT
17.03
+0.33 (1.98%)
After-hours: Apr 1, 2026, 7:42 PM EDT
Avalo Therapeutics Employees
Avalo Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 10 or 43.48% compared to the previous year.
Employees
33
Change (1Y)
10
Growth (1Y)
43.48%
Revenue / Employee
$1,788
Profits / Employee
-$2,371,485
Market Cap
380.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 10 | 43.48% | 33 | 0 |
| Dec 31, 2024 | 23 | 4 | 21.05% | 23 | 0 |
| Dec 31, 2023 | 19 | -1 | -5.00% | 19 | 0 |
| Dec 31, 2022 | 20 | -24 | -54.55% | 20 | 0 |
| Dec 31, 2021 | 44 | 13 | 41.94% | 42 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Bicycle Therapeutics | 288 |
| Puma Biotechnology | 179 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 95 |
| PureTech Health | 56 |
| Immuneering | 53 |
| Surrozen | 41 |
AVTX News
- 9 days ago - Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
- 5 months ago - Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 6 months ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 6 months ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire